Presentation of HIV-1 Envelope Trimers on the Surface of Silica Nanoparticles.


Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
01 2020
Historique:
received: 11 08 2019
revised: 19 09 2019
accepted: 25 10 2019
pubmed: 5 11 2019
medline: 25 3 2021
entrez: 5 11 2019
Statut: ppublish

Résumé

Inducing immune responses protecting from HIV infection or at least controlling replication poses a huge challenge to modern vaccinology. An increasingly discussed strategy to elicit a potent and broad neutralizing antibody response is the immobilization of HIV's trimeric envelope (Env) surface receptor on a nanoparticulate carrier. As a conceptual proof, we attached an Env variant (BG505 SOSIP.664) to highly stable and biocompatible silica nanoparticles (SiNPs) via site-specific covalent conjugation or nonspecific adsorption to SiNPs. First, we demonstrated the feasibility of SiNPs as platform for Env presentation by a thorough characterization process during which Env density, attachment stability, and antigenicity were evaluated for both formulations. Binding affinities to selected antibodies were in the low nanomolar range for both formulations confirming that the structural integrity of Env is retained after attachment. Second, we explored the recognition of SiNP conjugates by antigen presenting cells. Here, the uptake of Env attached to SiNPs via a site-specific covalent conjugation was 4.5-fold enhanced, whereas adsorbed Env resulted only in a moderate 1.4-fold increase compared with Env in its soluble form. Thus, we propose SiNPs with site-specifically and covalently conjugated Env preferably in a high density as a promising candidate for further investigations as vaccine platform.

Identifiants

pubmed: 31682830
pii: S0022-3549(19)30731-2
doi: 10.1016/j.xphs.2019.10.059
pii:
doi:

Substances chimiques

AIDS Vaccines 0
Antibodies, Neutralizing 0
Drug Carriers 0
HIV Envelope Protein gp120 0
HIV Envelope Protein gp41 0
gp120 protein, Human immunodeficiency virus 1 0
gp41 protein, Human immunodeficiency virus 1 0
Silicon Dioxide 7631-86-9

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

911-921

Informations de copyright

Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Auteurs

Stefanie Thalhauser (S)

Department of Pharmaceutical Technology, University Regensburg, Universitaetsstrasse. 31, 93040 Regensburg, Germany.

David Peterhoff (D)

Institute of Medical Microbiology and Hygiene, University Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Ralf Wagner (R)

Institute of Medical Microbiology and Hygiene, University Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. Electronic address: ralf.wagner@klinik.uni-regensburg.de.

Miriam Breunig (M)

Department of Pharmaceutical Technology, University Regensburg, Universitaetsstrasse. 31, 93040 Regensburg, Germany. Electronic address: miriam.breunig@chemie.uni-regensburg.de.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH